GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
X

Xiamen Kingdomway Group 002626.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

17.42

-0.17%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Xiamen Kingdomway Group

Its shares trade on Shenzhen under the ticker 002626.SZ. It has been listed since 28 October 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.37bn and net income of CN¥339.9m. At that date it held total assets of CN¥7.71bn and shareholders' equity of CN¥4.46bn.

Xiamen Kingdomway Group Co. engages in the research, development, manufacture and distribution of nutrition enhancers and bio-medical products. The company is headquartered in Xiamen, Fujian. The company went IPO on 2011-10-28. The firm mainly provides coenzyme Q10 series, including coenzyme Q10 lotion and Q10 powder; vitamin A (VA) series, including food level VA acetate, food level VA palmitate, food level VA palmitate powder, food level VA acetate powder, feed level VA powder and feed level VA acetate oil; health products - capsules series, as well as health products - tablets series, among others. The firm distributes its products within domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
28 Oct 2011
Employees
2,907

Leadership

Pay as last reported

  • Mr. Bin JiangChairman of the Board, since 1997CN¥690,710
  • Mr. Hang HongChief Financial Officer, Deputy General Manager, Director, since 2016
  • Ms. Xiaofang LiDeputy General Manager, Secretary of the Board
  • Mr. Jialiang ChenExecutive Deputy General Manager, Director, since 2001CN¥638,710
  • Mr. Guanghuang ZhanDeputy General ManagerCN¥732,774
  • Mr. Weihua GuDirector
  • Mr. Xiaote XuDirector
  • Mr. Dahong WangIndependent Director
  • Mr. Xiaojian WangIndependent Director
  • Mr. Geng ZongIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Xiamen, Fujian with 2,907 employees.
  • Offers coenzyme Q10 series including lotion and powder products.
  • Provides vitamin A series with various forms for food and feed use.

Weaknesses

  • No specific weaknesses mentioned in the provided data.
  • Limited information on product distribution channels beyond domestic and overseas markets.
  • No details on financial performance or market share provided.

Opportunities

  • Expansion into international markets for nutrition enhancers and bio-medical products.
  • Growth potential in health products like capsules and tablets series.
  • Increasing demand for vitamin A and coenzyme Q10 products in global markets.

Threats

  • Competition in the pharmaceutical and health care sectors.
  • Dependence on domestic market and overseas market distribution.
  • Potential regulatory challenges in pharmaceutical product manufacturing.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.